[go: up one dir, main page]

MX2019007981A - Terapeutica de proteinas para el tratamiento de celulas senescentes. - Google Patents

Terapeutica de proteinas para el tratamiento de celulas senescentes.

Info

Publication number
MX2019007981A
MX2019007981A MX2019007981A MX2019007981A MX2019007981A MX 2019007981 A MX2019007981 A MX 2019007981A MX 2019007981 A MX2019007981 A MX 2019007981A MX 2019007981 A MX2019007981 A MX 2019007981A MX 2019007981 A MX2019007981 A MX 2019007981A
Authority
MX
Mexico
Prior art keywords
conditionally active
methods
active proteins
senescent cells
treatment
Prior art date
Application number
MX2019007981A
Other languages
English (en)
Inventor
M Short Jay
Original Assignee
Bioatla Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Llc filed Critical Bioatla Llc
Publication of MX2019007981A publication Critical patent/MX2019007981A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Metodos para generar proteinas condicionalmente activas que se dirigen a las celulas senescentes y que son condicionalmente activas en un entorno extracelular de una célula senescente. Los metodos incluyen metodos de descubrimiento que utilizan bibliotecas de proteinas evolucionadas y ensayos que emplean concentraciones fisiológicas de componentes de fluidos corporales. Tambien se describen proteinas condicionalmente activas para matar o eliminar celulas senescentes, composiciones farmaceuticas que emplean estas proteinas condicionalmente activas y metodos para el tratamiento de enfermedades condiciones o trastornos relacionados con la edad que usan las mismas. Las proteinas condicionalmente activas pueden evolucionar aún mas, conjugarse con otras moléculas, enmascararse, reducir su actividad uniendo un resto escindible.
MX2019007981A 2017-01-03 2018-01-03 Terapeutica de proteinas para el tratamiento de celulas senescentes. MX2019007981A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762441745P 2017-01-03 2017-01-03
US201762509830P 2017-05-23 2017-05-23
PCT/US2018/012136 WO2018129007A1 (en) 2017-01-03 2018-01-03 Protein therapeutics for treatment of senescent cells

Publications (1)

Publication Number Publication Date
MX2019007981A true MX2019007981A (es) 2019-10-15

Family

ID=62791386

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007981A MX2019007981A (es) 2017-01-03 2018-01-03 Terapeutica de proteinas para el tratamiento de celulas senescentes.

Country Status (10)

Country Link
US (2) US20210230221A1 (es)
EP (1) EP3565846A4 (es)
JP (2) JP7790686B2 (es)
KR (2) KR20190095502A (es)
CN (1) CN110382543B (es)
AU (1) AU2018205629B2 (es)
CA (1) CA3048660A1 (es)
IL (1) IL267623A (es)
MX (1) MX2019007981A (es)
WO (1) WO2018129007A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2017128116A (ru) 2015-01-23 2019-02-26 Эразмус Юниверсити Медикал Сентр Роттердам Соединения, препятствующие старению, и способы их применения
KR20210069639A (ko) 2018-08-30 2021-06-11 에이치씨더블유 바이올로직스, 인크. 단일-사슬 키메라 폴리펩타이드 및 이의 용도
US11672826B2 (en) 2018-08-30 2023-06-13 HCW Biologics, Inc. Methods of treating aging-related disorders
JP7397874B2 (ja) 2018-08-30 2023-12-13 エイチシーダブリュー バイオロジックス インコーポレイテッド 多鎖キメラポリペプチドおよびその使用
KR20210072026A (ko) 2018-10-02 2021-06-16 루넬라 바이오테크 인코포레이티드 세놀리틱 약물로서 아지트로마이신 및 록시스로마이신 유도체
JP7088052B2 (ja) * 2018-12-12 2022-06-21 株式会社三洋物産 遊技機
JP7088053B2 (ja) * 2018-12-12 2022-06-21 株式会社三洋物産 遊技機
ES3009719T3 (en) 2019-04-18 2025-03-31 Bristol Myers Squibb Co Ipilimumab variants with enhanced specificity for binding at low ph
CN114269903B (zh) 2019-06-21 2025-11-25 免疫生物公司 多链嵌合多肽和其用途
KR102323971B1 (ko) 2019-10-01 2021-11-09 충북대학교 산학협력단 노화 억제 활성을 갖는 ｇｉｔ의 신규 용도
KR102204696B1 (ko) * 2019-12-10 2021-01-19 한국 한의학 연구원 1-모노에이코사펜타에노인을 유효성분으로 함유하는 주름개선용 조성물
CN115380045A (zh) 2020-02-11 2022-11-22 Hcw生物科技公司 激活调节性t细胞的方法
AU2021219720B2 (en) 2020-02-11 2025-10-02 Immunitybio, Inc. Chromatography resin and uses thereof
WO2021163369A2 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
US20230090099A1 (en) * 2020-02-21 2023-03-23 Cleara Biotech B.v. Improved anti-senescence compounds and uses thereof
US12497462B2 (en) 2020-04-29 2025-12-16 Immunitybio, Inc. Anti-CD26 proteins and uses thereof
WO2021247003A1 (en) * 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
KR20230031280A (ko) * 2020-06-01 2023-03-07 에이치씨더블유 바이올로직스, 인크. 노화 관련 장애의 치료 방법
JP2024514149A (ja) * 2021-04-13 2024-03-28 メモリアル スローン－ケタリング キャンサー センター ｕＰＡＲを標的とするＣＡＲ－Ｔ細胞及びその使用
CN114796451B (zh) * 2022-02-09 2023-06-06 上海瑞吉康生物医药有限公司 使用多肽治疗白内障的方法
EP4249912A1 (en) 2022-03-24 2023-09-27 Cleara Biotech B.V. Phosphorylation of p53 as a prognostic or diagnostic marker for the treatment of senescent cells in a mammal
CN115825262A (zh) * 2022-10-31 2023-03-21 深圳市罗湖区人民医院 一组差异小分子代谢产物在制备用于检测鼻咽癌的试剂中的应用
WO2024232976A1 (en) * 2023-05-07 2024-11-14 Bioatla, Inc. Protein therapeutics for treatment of senescent cells
CN116966301B (zh) * 2023-06-13 2026-01-09 浙江大学 Fap蛋白在制备抑制或清除衰老细胞试剂上的用途
KR20250011843A (ko) 2023-07-14 2025-01-22 (주)아모레퍼시픽 신규한 세노테라피 펩타이드 및 이를 포함하는 조성물
WO2025207911A1 (en) * 2024-03-28 2025-10-02 Senotherapeutix, Inc. Senolytic cell-penetrating peptide compositions and uses
CN119818651A (zh) * 2025-01-23 2025-04-15 杭州师范大学 Copg1蛋白在制备促进巨噬细胞m2极化的药物中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19756975A1 (de) * 1997-12-20 1999-06-24 Hoechst Marion Roussel De Gmbh Bindungspartner für Inhibitoren von cyclinabhängigen Kinasen und ihre Verwendung zur Suche nach Inhibitoren, zur Diagnose oder zur Therapie einer Erkrankung
EP2857516B1 (en) 2000-04-11 2017-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
AU2010222818B2 (en) * 2009-03-09 2015-05-14 Bioatla, Llc Mirac proteins
WO2010118419A2 (en) * 2009-04-10 2010-10-14 Haiyan Qi Novel anti-aging agents and methods to identify them
US20120005765A1 (en) 2010-07-01 2012-01-05 Saint Louis University Animal model for parkinson's disease
WO2012024616A1 (en) 2010-08-19 2012-02-23 Buck Institute For Age Research Methods of treating miild cognitive impairment (mci) and related discorders
AU2012352177A1 (en) 2011-12-13 2014-07-10 Buck Institute For Research On Aging Methods for improving medical therapies
WO2013158664A2 (en) 2012-04-17 2013-10-24 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US10279018B2 (en) 2012-12-03 2019-05-07 Unity Biotechnology, Inc. Immunogenic compositions for inducing an immune response for elimination of senescent cells
CA2922704A1 (en) 2013-05-24 2014-11-27 Neil R. Cashman Cell senescence markers as diagnostic and therapeutic targets
SG11201606239UA (en) 2014-01-28 2016-08-30 Buck Inst For Res On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
US10329556B2 (en) 2014-05-13 2019-06-25 Bioatla, Llc Conditionally active biological proteins
GB201409519D0 (en) * 2014-05-29 2014-07-16 Univ Leicester Senescent cell biomarkers
JP7286267B2 (ja) * 2014-08-28 2023-06-05 バイオアトラ インコーポレイテッド 修飾ｔ細胞に対する条件的活性型キメラ抗原受容体
KR20170044115A (ko) * 2014-09-03 2017-04-24 바이오아트라, 엘엘씨 동일한 진핵생물 세포 생산 숙주 내 조건부 활성 생체 단백질의 발견 및 제조
RU2017128116A (ru) * 2015-01-23 2019-02-26 Эразмус Юниверсити Медикал Сентр Роттердам Соединения, препятствующие старению, и способы их применения
JP7025214B2 (ja) * 2015-02-24 2022-02-24 バイオアトラ、エルエルシー 条件的活性型生物学的タンパク質
KR20160144846A (ko) * 2015-06-09 2016-12-19 삼성전자주식회사 세포 또는 개체의 노화를 감소시키기 위한 조성물 및 그의 용도

Also Published As

Publication number Publication date
CA3048660A1 (en) 2018-07-12
US20220282399A1 (en) 2022-09-08
JP7790686B2 (ja) 2025-12-23
AU2018205629B2 (en) 2025-02-06
CN110382543B (zh) 2023-12-26
JP2023116495A (ja) 2023-08-22
EP3565846A4 (en) 2020-01-22
EP3565846A1 (en) 2019-11-13
JP2020511951A (ja) 2020-04-23
AU2018205629A1 (en) 2019-07-11
IL267623A (en) 2019-08-29
KR20240116566A (ko) 2024-07-29
CN110382543A (zh) 2019-10-25
US20210230221A1 (en) 2021-07-29
KR20190095502A (ko) 2019-08-14
WO2018129007A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
MX2019007981A (es) Terapeutica de proteinas para el tratamiento de celulas senescentes.
MX2017010795A (es) Proteínas biológicas condicionalmente activas.
MX2021002107A (es) Derivado de dinucleotido ciclico novedoso y conjugado de anticuerpo-farmaco del mismo.
SG11201810270SA (en) Multispecific antigen-binding molecules having blood coagulation factor viii (fviii) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ing
ECSP19076732A (es) Compuestos de heteroarilo bicíclicos 6–6 fusionados y su uso como inhibidores de lats
CY1124612T1 (el) Συντηγμενοι δικυκλικοι sgc διεγερτες
MX2020003351A (es) Metodos, composiciones y elementos implantables que comprenden celulas activas.
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
CL2017001296A1 (es) Anticuerpos contra cd73 y sus usos
CL2019000112A1 (es) Proteínas quiméricas insecticidas, composiciones que las comprenden, y estrategias para el control de plagas de lepidópteros basadas en su uso. (divisional solicitud 201700895).
BR112017007765A2 (pt) composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
BR112016016658A2 (pt) proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
EA202090931A3 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
MX2021000295A (es) Compuestos inmunomoduladores dimericos contra mecanismos basados en cereblon.
BR112015024605A2 (pt) sistemas e métodos para a produção visada de proteína terapêutica dentro de célula alvo
NO20090598L (no) 6,9-disubstituerte purinderivater og deres anvendelse for behandling av hud
UY37379A (es) Derivados de n-(piridin-2-il)piridina-sulfonamida y su uso en el tratamiento de enfermedades
UY31305A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
SV2003001148A (es) Derivados de benzamida tiazol y composciones farmaceuticas para inhibir la proliferacion de celulas, y metodos para su utilizacion ref. no.0097-01-sv
CY1124922T1 (el) Καινοτομος σταθερη φαρμακοτεχνικη μορφη για αντισωματα fxia
EA202191122A1 (ru) СЕЛЕКТИВНЫЕ К RGMc ИНГИБИТОРЫ И ИХ ПРИМЕНЕНИЕ
MX2020004712A (es) Vesiculas extracelulares modificadas geneticamente con proteinas.
MX2021000401A (es) Nuevas proteinas de fusion especificas para cd137 y pd-l1.
BR112019000005A2 (pt) inibidores de pde9 para o tratamento de doenças periféricas
BR112014004945A2 (pt) agentes lipídicos de inseticida isolados de fugos entomopatogênicos e usos dos mesmos